Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
1 hedge funds and large institutions have $16 invested in Avadel Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
50% less funds holding
Funds holding: 2 → 1 (-1)
96% less capital invested
Capital invested by funds: $442 → $16 (-$426)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$426 |
AVDL Hedge Fund Activity: Q2 2026 in Review
1 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2026, worth a combined $16 — down 96% from $442 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of AVDL and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was IFP Advisors, exiting entirely with an estimated $426 sold.
- 1 institutional investor held Avadel Pharmaceuticals (AVDL) as of Q2 2026, down from 2 in Q1 2026.
- Funds reported $16 of Avadel Pharmaceuticals stock for Q2 2026, down 96% quarter-over-quarter.
- 0 funds opened new Avadel Pharmaceuticals positions in Q2 2026 and 1 closed out, a net change of -1 holder.
- The largest Avadel Pharmaceuticals seller in Q2 2026 was IFP Advisors, an estimated $426 sold.
Based on aggregated 13F filings for Q2 2026.